A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers
← catalyst calendarSponsored by Nurix Therapeutics, Inc. (industry) · NRIX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
223actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-30 | actual | When the study began enrolling |
| Primary completion | 2026-05-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-01 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: NX-5948 — also filed as Bexobrutideg
- Drug: Esomeprazole
- Drug: Placebo
- Drug: Famotidine
- Drug: Midazolam
- Drug: Digoxin
- Drug: Rosuvastatin
- Drug: Quinidine
- Drug: NX-5948 — also filed as Bexobrutideg
Primary outcomes
what the primary-completion date above is the date OFArea under the concentration-time curve from time 0 to last observed non-zero concentration (AUC0-t): NX-5948
measured 9 weeks
Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf): NX-5948
measured 9 weeks
Maximum observed concentration (Cmax): NX-5948
measured 9 weeks
AUC0-t: Midazolam, rosuvastatin, or digoxin
measured 9 weeks
AUC0-inf: Midazolam, rosuvastatin, or digoxin
measured 9 weeks
Cmax: Midazolam, rosuvastatin, or digoxin
measured 9 weeks
Placebo-corrected change from baseline QT interval (QTc) as measured by electrocardiogram
measured Baseline, 9 weeks
Number of participants with treatment-emergent adverse events
measured Up to 10 weeks
Permalink · NRIX's whole pipeline · Catalyst calendar · Every registered study · What changed